Few discoveries have accelerated biomedical research faster than CRISPR, the protein-based gene editing tool that allows scientists to precisely manipulate individual genes on a molecular level. Startup company KSQ Therapeutics, co-founded by KI members Eric Lander, David Sabatini, and Jonathan Weissman, leverages the investigators' CRISPR-based technologies to decipher the role of genes in diseases like cancer and apply these insights to therapeutic development.